KR101682108B1 - Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient - Google Patents
Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient Download PDFInfo
- Publication number
- KR101682108B1 KR101682108B1 KR1020150141399A KR20150141399A KR101682108B1 KR 101682108 B1 KR101682108 B1 KR 101682108B1 KR 1020150141399 A KR1020150141399 A KR 1020150141399A KR 20150141399 A KR20150141399 A KR 20150141399A KR 101682108 B1 KR101682108 B1 KR 101682108B1
- Authority
- KR
- South Korea
- Prior art keywords
- extracellular polysaccharide
- culture
- weight
- mycelial
- mycelium
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 32
- 239000004480 active ingredient Substances 0.000 title claims abstract description 13
- 241001466515 Emmia lacerata Species 0.000 title claims abstract description 4
- 230000017531 blood circulation Effects 0.000 title description 16
- 230000006872 improvement Effects 0.000 title description 4
- 229920002444 Exopolysaccharide Polymers 0.000 title description 2
- 150000004676 glycans Chemical class 0.000 claims abstract description 41
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 41
- 239000005017 polysaccharide Substances 0.000 claims abstract description 41
- 239000000843 powder Substances 0.000 claims abstract description 27
- 239000007788 liquid Substances 0.000 claims abstract description 24
- 239000000284 extract Substances 0.000 claims abstract description 18
- 230000036541 health Effects 0.000 claims abstract description 12
- 230000023555 blood coagulation Effects 0.000 claims abstract description 11
- 235000013376 functional food Nutrition 0.000 claims abstract description 10
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 16
- 239000001963 growth medium Substances 0.000 claims description 15
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 claims description 8
- 102000004169 proteins and genes Human genes 0.000 claims description 8
- 108090000623 proteins and genes Proteins 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- 239000008103 glucose Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims description 6
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 6
- 238000009630 liquid culture Methods 0.000 claims description 6
- 239000002609 medium Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 5
- 241001440188 Lacera Species 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- 229910052943 magnesium sulfate Inorganic materials 0.000 claims description 4
- 235000019341 magnesium sulphate Nutrition 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 claims description 4
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 claims description 3
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims description 3
- 235000013361 beverage Nutrition 0.000 claims description 3
- 239000001569 carbon dioxide Substances 0.000 claims description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 claims description 3
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 claims description 3
- 229930182830 galactose Natural products 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 235000019219 chocolate Nutrition 0.000 claims description 2
- 235000009508 confectionery Nutrition 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 claims description 2
- 229910000160 potassium phosphate Inorganic materials 0.000 claims description 2
- 235000011009 potassium phosphates Nutrition 0.000 claims description 2
- 230000002829 reductive effect Effects 0.000 claims description 2
- 229930003231 vitamin Natural products 0.000 claims description 2
- 239000011782 vitamin Substances 0.000 claims description 2
- 229940088594 vitamin Drugs 0.000 claims description 2
- 235000013343 vitamin Nutrition 0.000 claims description 2
- 150000003722 vitamin derivatives Chemical class 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims 2
- 241001122767 Theaceae Species 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 235000015872 dietary supplement Nutrition 0.000 claims 1
- 235000013312 flour Nutrition 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 abstract description 18
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 13
- 239000000243 solution Substances 0.000 description 23
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- 230000000694 effects Effects 0.000 description 13
- 238000002360 preparation method Methods 0.000 description 13
- 239000001965 potato dextrose agar Substances 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 108010094028 Prothrombin Proteins 0.000 description 7
- 102100027378 Prothrombin Human genes 0.000 description 7
- 229940039716 prothrombin Drugs 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 230000001461 cytolytic effect Effects 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 5
- 108010000499 Thromboplastin Proteins 0.000 description 5
- 102000002262 Thromboplastin Human genes 0.000 description 5
- 229960001138 acetylsalicylic acid Drugs 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 230000004087 circulation Effects 0.000 description 5
- 239000012153 distilled water Substances 0.000 description 5
- 238000005227 gel permeation chromatography Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- PGOHTUIFYSHAQG-LJSDBVFPSA-N (2S)-6-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-5-amino-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[(2S)-1-[(2S,3R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-4-methylsulfanylbutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]propanoyl]pyrrolidine-2-carbonyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-methylpentanoyl]amino]acetyl]amino]-3-hydroxypropanoyl]amino]-4-methylpentanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-5-carbamimidamidopentanoyl]amino]-5-oxopentanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-oxopentanoyl]amino]-3-phenylpropanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-methylbutanoyl]amino]-4-methylpentanoyl]amino]-4-oxobutanoyl]amino]-5-carbamimidamidopentanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-4-carboxybutanoyl]amino]-5-oxopentanoyl]amino]hexanoic acid Chemical compound CSCC[C@H](N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc1c[nH]c2ccccc12)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(O)=O PGOHTUIFYSHAQG-LJSDBVFPSA-N 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 230000036961 partial effect Effects 0.000 description 4
- 239000013641 positive control Substances 0.000 description 4
- 244000287680 Garcinia dulcis Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- 241000208340 Araliaceae Species 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010008111 Cerebral haemorrhage Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 2
- 235000003140 Panax quinquefolius Nutrition 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 208000011775 arteriosclerosis disease Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010008118 cerebral infarction Diseases 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000008298 dragée Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 235000008434 ginseng Nutrition 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 208000019622 heart disease Diseases 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 208000031225 myocardial ischemia Diseases 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 229920005862 polyol Polymers 0.000 description 2
- 150000003077 polyols Chemical class 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 1
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 206010008132 Cerebral thrombosis Diseases 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 108010049003 Fibrinogen Proteins 0.000 description 1
- 102000008946 Fibrinogen Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 244000068988 Glycine max Species 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- 206010018852 Haematoma Diseases 0.000 description 1
- 229920002488 Hemicellulose Polymers 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000019764 Soybean Meal Nutrition 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000005158 Subtilisins Human genes 0.000 description 1
- 108010056079 Subtilisins Proteins 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003114 blood coagulation factor Substances 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 208000027744 congestion Diseases 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 229940012952 fibrinogen Drugs 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000001965 increasing effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 230000006623 intrinsic pathway Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- OQUKIQWCVTZJAF-UHFFFAOYSA-N phenol;sulfuric acid Chemical compound OS(O)(=O)=O.OC1=CC=CC=C1 OQUKIQWCVTZJAF-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000002639 sodium chloride Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000004455 soybean meal Substances 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 238000009777 vacuum freeze-drying Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Plant Substances (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention relates to an extracellular polysaccharide produced by Ceriporia lacerata ; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or an extract of the mycelial body as an active ingredient. The composition of the present invention is excellent in blood coagulation inhibitory effect, and is useful as a pharmaceutical composition for preventing or treating thrombotic diseases and for preventing or improving thrombotic diseases It can be usefully used as a health functional food.
Description
The present invention relates to an extracellular polysaccharide produced by Ceriporia lacerata ; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or an extract of the mycelium culture liquid as an active ingredient.
Recently, circulatory diseases such as arteriosclerosis, cerebral hemorrhage, hypertension, heart disease, stroke, cerebral infarction and ischemic heart disease have been the leading causes of death in Korea as well as advanced countries. Thrombosis is recognized as a pathological phenomenon mediated by excessive platelet aggregation, which causes blood circulation disorders. In addition, the aging of blood vessels breaks the balance of the blood coagulation system and creates thrombosis in the body. Such thrombosis interferes with circulation of blood and nutrition and oxygen supply to tissues and causes various diseases.
Blood coagulation is a process in which coagulation factors in the blood are continually activated to eventually change the fibrinogen to fibrin, leading to a blood clot, which is called the contact system. It is caused by an extrinsic factor that initiates activation by the intrinsic pathway and tissue factor.
Furthermore, the extent to which a substance or natural product affects the endogenous pathway of the coagulation cascade can be assessed using Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT), respectively .
As a conventional technique related thereto, Korean Patent Registration No. 10-1259499 discloses a method for extracting ginseng lipid soluble components and a composition for improving circulation comprising ginseng lipid soluble components extracted by the above method.
On the other hand, Sellapora lacerata is a kind of white rot fungus, and it is known that it performs co-metabolism called lignin decomposition in order to utilize carbon sources such as cellulose, hemicellulose, other polysaccharides and glycerol in an ecosystem.
Regarding the medical treatment application using the serpia lacrosera, Korean Patent Registration No. 10-1031605 filed by the present inventors has only known heretofore for the diabetes treatment of the extract of the culture liquid of Serrachia lacera rata , And the blood circulation improving effect by using Sera lipolyla serarata has not been reported yet.
Accordingly, the present inventors have found that an extracellular polysaccharide separated from a cerporolactacera; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or the extract of the mycelium culture liquid shows blood circulation improving effect, thereby completing the present invention.
An object of the present invention is to provide a blood circulation improving composition containing an active ingredient produced by ceriplora lactaclora; A pharmaceutical composition for preventing or treating thrombotic diseases; And a health functional food for preventing or improving thrombotic diseases.
In order to accomplish the above object, the present invention provides an extracellular polysaccharide produced by a cellulolytic enzyme; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or a composition for improving blood circulation comprising the extract of the mycelial body as an active ingredient, a pharmaceutical composition for preventing or treating thrombotic diseases, and a health functional food for preventing or improving thrombotic diseases.
An extracellular polysaccharide produced by a cellulolytic enzyme according to the present invention; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or a composition for improving blood circulation comprising the extract of the mycelial body as an active ingredient is a composition having an excellent blood circulation improving activity by prolonging blood clotting time by reducing prothrombin activity; A pharmaceutical composition for preventing and treating thrombotic diseases including the same; Or as a health functional food for prevention and improvement of thrombotic diseases.
Hereinafter, the present invention will be described in detail.
The present invention relates to an extracellular polysaccharide produced by a cellulolytic enzyme; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or an extract of the mycelium culture liquid as an active ingredient.
Wherein the extracellular polysaccharide comprises from 40 to 60% by weight of sugar, from 30 to 40% by weight of protein, from 40 to 50% by weight of sugar and from 32 to 38% by weight of protein, or from 43 to 47% % Protein, more specifically about 45 wt% sugar and about 34 wt% protein.
The sugar may contain mannose, galactose and glucose.
The extracellular polysaccharide may have a molecular weight of 100 to 150 kDa, 110 to 140 kDa or 115 to 125 kDa, and more specifically about 120 kDa.
In one preferred embodiment, the extracellular polysaccharide is produced by: (a) liquid culturing mycelia lacticera mycelium to prepare a culture medium of a seriposita lactamera mycelium; (b) drying and cultivating the culture medium of the above-mentioned sera lipolactacera mycelium; And (c) a step of extracting the culture medium of the cultured Mycelium lacticera mycelium with a solvent, followed by filtration and concentration under reduced pressure.
The medium for liquid culture of the mycelium of seripositive Lactacera in the step (a) is selected from the group consisting of sugar, glucose, starch, water, barley, soybean powder, magnesium sulfate (MgSO 4 ), potassium monophosphate (KH 2 PO 4 ), potassium diphosphate (K 2 HPO 4 ) and water, and the hydrogen ion concentration may be pH 4.5 to 6.0.
As a specific example, the culture medium contains 0.2 to 3% by weight of sugar, 0.2 to 3% by weight of glucose, 0.2 to 4% by weight of starch, 0.1 to 0.5% by weight of water, 0.1 to 0.5% % by weight, magnesium sulfate (MgSO 4) 0.05 ~ 0.1 wt%, 1 potassium phosphate (KH 2 PO 4) containing 0.05 ~ 0.25%, dipotassium hydrogen phosphate (K 2 HPO 4) 0.05 to 0.25% by weight and the residual amount of water can do.
The liquid culture in the step (a) can be performed under a blue LED light source and can be performed by maintaining the concentration of carbon dioxide at 1,000 to 2,000 ppm.
For example, the liquid culture is maintained at a pH of 4.5 to 6.0 at 20 to 25 ° C, a blue LED as a light source, and 0.1 to 0.8 LUX as an illuminance, and air is injected at 0.5 to 1.5 kgf / The concentration of carbon dioxide can be carried out for 8 to 13 days while maintaining the concentration of 1,000 to 2,000 ppm and can be carried out at 20 to 28 ° C, pH 4.5 to 6.0, 0.5 to 2.0 kgf / cm 2, and 1,000 to 2,000 ppm for 5 to 15 days have. When liquid culture is carried out under the above-described conditions, the content of extracellular polysaccharide is high, which is preferable.
As a parent strain in step (a), one of the excellent strains stored at 1-5 ° C. in a PDA (Potato dextrose agar) medium was inoculated into an Erlenmeyer flask using a PDB (Potato dextrose broth) ° C, and cultured for 7 to 9 days. At this time, the amount of the mycelium to be added to the inoculum is preferably about 0.5% (w / v) based on the amount of the solution to be cultured. Since the amount of extracellular polysaccharide is not so high as much as the amount of mycelium (% / 100 ml, w / v), the composition of the medium is not the best nutritional ratio and environmental condition for growth of the mycelium, It is preferable to apply selective culture conditions in which the cells are formed.
The culture solution can be separated and purified into mycelium and an aqueous solution. For separation and purification, the solution obtained by removing the mycelium with a centrifugal separator can be repeatedly refined with a multi-sheet filter press and a vibrating centrifugal separator (PALLSEP), and then irradiated with ultraviolet rays (UV) for 1 minute. In addition, it is necessary to store the solution in a sealed state after removing the oxygen, because when the mycelium exists in the solution, the growth of the mycelium changes the content of the active ingredient.
In the step (b), the mycelial culture solution prepared in the step (a) may be pulverized by vacuum drying or freeze-drying. The drying is preferably carried out at a temperature of 40 DEG C or lower, more specifically, at a temperature of 30 DEG C or lower for 48 to 96 hours in order to prevent the disappearance of the active substance. In the drying in the step (b), it is preferable to use a vacuum freeze dryer rather than a vacuum dryer in which the evaporation temperature is set to be relatively high, since the change in effective substance content is minimized.
In step (c), the extracellular polysaccharide, which is an active ingredient of the composition according to the present invention, is isolated and prepared by extracting the dried powder of the mycelial liquid obtained in step (b) with a solvent. Specifically, 100 mg of distilled water was added to 3 to 10 g of dried powder, and the suspension was centrifuged at 5,000 rpm to 10,000 rpm for 10 minutes to 30 minutes. To the supernatant was added 2 to 3 times Add the solvent and put in a refrigerator at 1 ~ 5 ℃ for 10 ~ 15 hours. After centrifuging the supernatant alone at 5,000 rpm to 10,000 rpm for 10 minutes to 30 minutes, the crude polysaccharide can be recovered by recovering the precipitate. The crude extracellular polysaccharide is preferably vacuum-freeze-dried at 30 DEG C or lower.
The extraction solvent may be a solvent selected from the group consisting of water, a lower alcohol having 1 to 4 carbon atoms, acetone, ether, chloroform and ethyl acetate, or a mixture thereof. More specifically, water, methanol, ethanol, , Acetone and ethyl acetate, or a mixture thereof, more preferably water or an aqueous solution of 50 to 80% (w / w) of ethanol.
The blood circulation improving composition of the present invention may exhibit an effect of inhibiting blood coagulation, and the effect of inhibiting blood coagulation is an effect of prolonging blood coagulation time by decreasing prothrombin activity. According to one embodiment of the present invention, the composition for improving circulation of the present invention exhibits a blood coagulation inhibitory activity which is excellent in prothrombin time and activated partial thromboplastin time increasing effect in the plasma of the administration group.
An extracellular polysaccharide produced by the cellulolytic enzyme of the present invention; A mycelial culture solution of ceriplora lacerata containing the extracellular polysaccharide; A dry powder of the mycelial culture liquid; Or a composition for improving blood circulation comprising the extract of the mycelial body culture liquid may be used as an additive for a pharmaceutical composition and / or a health functional food for the purpose of exhibiting a blood coagulation inhibiting effect. In this case, It can be adjusted appropriately.
The extracellular polysaccharide may be contained in an amount of 0.1 to 80% by weight, and more preferably 0.1 to 50% by weight, based on the total weight of the composition for improving circulation. The extracellular polysaccharide may be a mycelial culture solution, May suitably be included in an amount corresponding to the content of the extracellular polysaccharide. More specifically, however, an extracellular polysaccharide; A culture fluid containing the same; A dry powder of the culture solution; Alternatively, the effective amount of the extract of the culture can be appropriately controlled depending on the method and purpose of use of the composition.
The present invention also provides a pharmaceutical composition for the prevention or treatment of thrombotic diseases comprising the composition for improving blood as described above.
The pharmaceutical composition for the prevention or treatment of thrombotic diseases comprises an extracellular polysaccharide produced by three lipolactacera; A culture solution of mycelium of Sellapora lacera rata containing the same; A dry powder of the mycelial culture liquid; Or an appropriate carrier, excipient and diluent which are conventionally used in addition to those containing the extract of the mycelial liquid as an active ingredient.
Each of the pharmaceutical compositions according to the present invention can be formulated according to a conventional method. Suitable formulations include, but are not limited to, tablets, pills, powders, granules, dragees, hard or soft capsules, solutions, suspensions or emulsions, injections, suppositories and the like.
The pharmaceutical composition according to the present invention can be prepared into a suitable formulation using a pharmaceutically inert organic or inorganic carrier. That is, when the formulations are tablets, coated tablets, dragees and hard capsules, lactose, sucrose, starch or derivatives thereof, talc, calcium carbonate, gelatin, stearic acid or salts thereof may be used. Also, vegetable oils, waxes, fats, semi-solid and liquid polyols may be used when the formulations are soft capsules. In addition, when the formulation is in the form of a solution or a syrup, water, polyol, glycerol, vegetable oil and the like may be used.
The pharmaceutical composition according to the present invention may further contain preservatives, stabilizers, wetting agents, emulsifiers, solubilizers, sweeteners, coloring agents, osmotic pressure regulators, antioxidants and the like in addition to the above carriers.
The method of administering the pharmaceutical composition according to the present invention can be easily selected according to the formulation, and can be administered orally or parenterally. The dosage may vary depending on the patient's age, sex, weight, degree of pathology, and route of administration, but is generally in the range of 5 to 500 mg / kg body weight based on the extracellular polysaccharide, mg / kg body weight may be administered once or three times a day. However, the dosages do not in any way limit the scope of the invention.
The pharmaceutical composition according to the present invention not only provides a superior blood coagulation inhibition effect but also has little toxicity and side effects caused by drugs and can be used safely even when taken for a long time for the purpose of treatment or prevention of thrombotic diseases. Accordingly, the pharmaceutical composition of the present invention is useful for the treatment of thrombotic diseases such as arteriosclerosis, cerebral hemorrhage, hypertension, heart disease, stroke, cerebral infarction, ischemic heart disease, cerebral thrombosis, congestion, hematoma, thrombosis and myocardial infarction Can be used for prevention or treatment.
The present invention provides a health functional food for preventing or ameliorating a thrombotic disease comprising the composition for improving circulation as described above.
The health functional food according to the present invention may be in the form of a powder, a granule, a tablet, a capsule or a drink, and may be a candy, a chocolate, a beverage, a gum, a tea, a vitamin complex,
Herein, the extracellular polysaccharide according to the present invention contained in the health functional food; A mycelial culture fluid containing the same; A dry powder of the mycelial culture liquid; Or the content of the extract of the mycelial culture liquid may be usually 0.01 to 50% by weight, specifically 0.1 to 20% by weight, based on the total weight of the whole food. In the case of a health drink composition, it may be contained in an amount of 0.02 to 10 g, specifically 0.3 to 1 g, based on 100 ml of the health drink composition.
The food may be an extracellular polysaccharide of the present invention; A culture solution of mycelium of Sellapora lacera rata containing the same; A dry powder of the mycelial culture liquid; Or a food-acceptable food-aid additive together with the extract of the mycelial culture broth.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are for illustrative purposes only and are not intended to limit the scope of the present invention.
[ Example ]
Manufacturing example
One.
Three Li Pori
Rock Serrat
Mycelial cultures, their dry powders, extracts and extracellular polysaccharides (
exopolysaccharide; Hereinafter referred to as "EPS")
Produce
1.1 Three Li Pori Rock Serrat Mycelial culture preparation
The bacterium cultivated by subculture was stored frozen at -80 ℃ and stored in a PDA (Potato dextrose agar) medium (87 plastic culture (Hereinafter referred to as "PDA culture broth") was stored in a refrigerator at 4 ° C for 2 to 3 times after passage in a refrigerator (Difco, Becton Dickinson and Company). Then, 600 ml of a PDB (Potato dextrose broth) medium (Difco, Becton Dickinson and Company) was added to the Erlenmeyer flask. One PDB culture was added to the flask, followed by shake culture for 8 days to obtain a PDB culture.
Thereafter, a mixture of 1.5% by weight of sugar, 0.5% by weight of glucose, 0.5% by weight of potato starch, 0.25% by weight of water, 0.25% by weight of blood, 0.75% by weight of soybean meal, 0.05% by weight of magnesium sulfate (MgSO 4 ) 2 PO 4 ) 0.05% by weight, potassium diphosphate (K 2 HPO 4 ) 0.05% by weight and the remaining amount of water was sterilized in an 800 L fermenter at 121 ° C and 1.5 kgf / cm 2 for 20 minutes, , 600 ml of the above-mentioned PDB culture strain to be used as a starter was inoculated while air was being supplied at a rate of 0.5 to 1.5 kgf / cm < 2 >, while the light source was a blue LED and maintained an illuminance of 0.5 LUX. , Mycelium culture of Sera lipolas serrata was prepared by liquid culture of Escherichia coli sera at a constant temperature of 23 DEG C for 10 days.
1.2 Three Li Pori Lacerata Preparation of dry powder of mycelial culture
The mycelial culture of the cellulolytic enzyme solution prepared in Preparation Example 1.1 was lyophilized at 25 DEG C for 72 hours by using a vacuum freeze dryer to be pulverized to prepare a dry powder of the cultured mycelium lacticera mycelium.
1.3 Three Li Pori Lacerata Extract preparation of culture medium
100 ml of distilled water was added to 5 g of the dry powder of the culture medium of the cellulolytic enzyme solution prepared in Preparation Example 1.2, and the mixture was suspended well, centrifuged at 8,000 rpm for 20 minutes, Three times the amount of ethanol was added and allowed to stand at 4 占 폚 for 12 hours. Thereafter, the supernatant was taken from the column, and an extract of the cultured Mycelium lacticera mycelium was prepared.
1.4 Three Li Pori Lacerata Preparation of EPS from culture medium
After centrifugation (8,000 rpm, 20 minutes) of the extract of the culture medium of the mycelial growth medium prepared in Preparation Example 1.3, the precipitate was recovered to obtain crude EPS. The crude EPS was vacuum-lyophilized at 25 ° C for 72 hours to obtain an EPS produced by Sera lipolactacrata.
Example
1. Characterization of EPS
1.1 Gel Permeation Chromatography, GPC Molecular weight measurement of EPS using
The EPS prepared in Preparation Example 1 was dissolved in a solution of 0.1 M Na 2 SO 4 /0.05 M NaN 3 (pH adjusted to 4 with glacial acetic acid) to a concentration of 1% (w / v) After centrifugation for 0.5 hr, only the supernatant was filtered with a 0.45 탆 syringe filter and analyzed by GPC.
Specifically, the GPC analysis conditions were a refractive index as a detector and a GPC column using OHpak SB 805 HQ (Shodex, Japan). The mobile phase was adjusted to pH 4 with 0.1 M Na 2 SO 4 /0.05 M NaN 3 The flow rate of the mobile phase was allowed to flow at a rate of 1.0 ml / min. Standard curves were prepared using dextran (American Polymer Corporation, USA) with different molecular weights (130 kDa, 400 kDa, 770 kDa and 1200 kDa) and refractive index (RI) Knauer K-2310 Germany) was used to measure the molecular weight of EPS. The measurement conditions are summarized in Table 1 below.
As a result, the molecular weight of the EPS of the present invention was found to be 120 kDa.
1.2 Measurement of sugar and protein content of EPS
The EPS prepared in Preparation Example 1 was subjected to second purification and treated with a protein hydrolyzing enzyme to measure sugar and protein content.
Specifically, the first purified EPS (EPS prepared in Preparation Example 1) was dissolved in distilled water and centrifuged at 8,000 rpm for 20 minutes to separate the supernatant. Then, the separated supernatant was diluted to 2 to 3 times its amount Ethanol was added and the mixture was placed in a refrigerator (4 캜) for 12 hours. After the supernatant was centrifuged again at 8,000 rpm for 20 minutes, the precipitate was recovered and the second purified EPS was obtained. After the second purified EPS was dissolved in distilled water, the protein hydrolyzing enzyme alcalase was treated at a concentration of 0.5% (w / v) at 50 ° C for 30 minutes.
The sugar content was measured by the phenol-sulfuric acid method. 25 μl of 80% phenol was added to 1 ml of diluted sample. 2.5 ml of sulfuric acid was added, and the solution was cooled at room temperature and absorbance was measured at 465 nm. Protein content was also measured by the BCA method (Smith PK et al., Analytical Biochemistry , 150 (1): 76-85, 1985) and bovine serum albumin was used as a standard.
The sugar content and the protein content measured as described above are shown in Table 2, and the sugar content was 45 to 51% by weight and the protein content was 33 to 34% by weight.
Also, as a result of the sugar composition analysis of EPS, it was found that EPS mainly contains mannose, galactose and glucose.
Example
2. Evaluation of blood circulation improvement efficacy
The efficacy of improving the blood circulation of the dry powder of the culture medium of the mycelium of ceriplora lactaceras of Production Example 1.2 and the EPS of Production Example 1.4 was evaluated.
Specifically, the blood circulation improving effect was obtained by collecting whole blood in male SD rats, separating plasma by centrifugation at 3,000 rpm for 10 minutes at 4 ° C, measuring the prothrombin time (PT) and the activated partial thromboplastin time (aPTT) Respectively.
Prothrombin time was determined by adding 100 μl of the rat-derived plasma and 10 μl of various concentrations of the sample to a tube of Amelung coagulometer KC-1A (Japan), heating at 37 ° C for 1 minute, and then adding 200 μl of prothrombin time reagent hemostasis (TM) thromboplastin-D, manufactured by Thermo Scientific Co.) was added and the time until the plasma coagulated was measured. The test group was treated with distilled water and the experimental group was treated with 10 μg / ml of dry powder of the cultured myceliallacerase solution of Preparation 1.2 or 3 mg of Sepholyaraccharae EPS of Preparation Example 1.4, 100 μg / ml, 300 μg / ml or 500 μg / ml, and the positive control group was treated with 100 μg / ml of aspirin (Sigma Co., USA). The results are shown in Tables 3 and 4 below.
The activated partial thromboplastin time was determined by adding 100 μl of the rat-derived plasma and 10 μl of the sample solution at various concentrations to a tube of Amelung coagulometer KC-1A (Japan), heating at 37 ° C for 3 minutes, and then adding 100 μl of aPTT Reagent (Sigma, ALEXINTM) was added and incubated again at 37 ° C for 3 minutes. After the addition of 100 ㎍ calcium chloride (CaCl 2 ) (20 mM), the time until the plasma was solidified was measured. The results are shown in Tables 3 and 4 below.
Control group
(second)
Control group
(second)
As shown in Table 3 above, the experimental group treated with the dry powder of the culture medium of the preparation of Sera lipolactacera of Preparation 1.2 compared with the positive control treated with 100 ㎍ / ml of aspirin showed similar or better blood circulation improvement The effect was confirmed.
In addition, as shown in Table 4, compared with the positive control treated with 100 ㎍ / ml of aspirin, the experimental group treated with EPS of Production Example 1.4 showed similar or superior blood circulation improving effect as that of the positive control group.
Claims (13)
Wherein said extracellular polysaccharide comprises 40 to 60% by weight of sugar and 30 to 40% by weight of protein and has a molecular weight of 100 to 150 kDa.
Wherein said extracellular polysaccharide comprises 43 to 47% by weight of sugar and 33 to 36% by weight of protein and has a molecular weight of 115 to 125 kDa.
Wherein the saccharide contains mannose, galactose and glucose.
Wherein the extracellular polysaccharide is selected from
(a) liquid culturing the mycelium of ceriplora lactaclora to prepare a culture medium of a seriposita lactamera mycelium;
(b) drying and cultivating the culture medium of the mycelium of ceriplora lactaclora; And
(c) a step of extracting the culture medium of the mycelium of cerolaria lacera with a solvent, followed by filtration and concentration under reduced pressure.
The liquid medium for the culture is sugar, glucose, starch, water, for maekbun, soy flour, magnesium sulfate (MgSO 4), 1 potassium phosphate (KH 2 PO 4), 2 potassium phosphate (K 2 HPO 4) and water Wherein the hydrogen ion concentration is pH 4.5 to 6.0.
Wherein the liquid culture is performed under a blue LED light source and is carried out by maintaining the concentration of carbon dioxide at 1,000 to 2,000 ppm.
Wherein the extracellular polysaccharide is contained in an amount of 0.1 to 80% by weight based on the total weight of the composition for inhibiting blood coagulation.
Wherein said health functional food is in the form of powder, granule, tablet, capsule or beverage.
Wherein said health functional food is candy, chocolate, beverage, gum, tea, vitamin complex or health supplement.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150141399A KR101682108B1 (en) | 2015-10-08 | 2015-10-08 | Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
| PCT/KR2016/011255 WO2017061819A1 (en) | 2015-10-08 | 2016-10-07 | Composition for improving blood circulation containing extracellular polysaccharide produced from ceriporia lacerata as active ingredient |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020150141399A KR101682108B1 (en) | 2015-10-08 | 2015-10-08 | Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR101682108B1 true KR101682108B1 (en) | 2016-12-02 |
Family
ID=57571608
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020150141399A KR101682108B1 (en) | 2015-10-08 | 2015-10-08 | Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR101682108B1 (en) |
| WO (1) | WO2017061819A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11819510B2 (en) | 2020-09-14 | 2023-11-21 | Advanced Protein Technologies Corp. | Food composition for ameliorating cerebrovascular diseases containing 2′- fucosyllactose and pharmaceutical composition for preventing or treating cerebrovascular diseases containing 2′-fucosyllactose |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112608871B (en) * | 2021-01-12 | 2022-11-01 | 江南大学 | Method for producing probiotic active substances by high-density fermentation of bacillus thuringiensis |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101031605B1 (en) | 2010-11-11 | 2011-04-27 | 김병천 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
| KR101259499B1 (en) | 2012-06-01 | 2013-05-06 | (주)다인내추럴 | Compositions for improving blood circulation comprising fat-soluble ingredients of ginseng |
| KR101444614B1 (en) * | 2013-08-01 | 2014-09-26 | 계명대학교 산학협력단 | Method for producing fermented material with high GABA by mixed culture of Ceriporia lacerata and Lactobacillus |
| KR20150103690A (en) * | 2013-01-18 | 2015-09-11 | (주)퓨젠바이오농업회사법인 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101522415B1 (en) * | 2015-02-26 | 2015-05-21 | 한상선 | Cosmetic composition including an acanthus extract of ceriporia lacerata and cosmetics using the same |
-
2015
- 2015-10-08 KR KR1020150141399A patent/KR101682108B1/en active IP Right Grant
-
2016
- 2016-10-07 WO PCT/KR2016/011255 patent/WO2017061819A1/en active Application Filing
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101031605B1 (en) | 2010-11-11 | 2011-04-27 | 김병천 | Manufacturing method of culture extract of ceriporia lacerata for the therapy of diabetic diseases and culture extract of ceriporia lacerata using the same |
| KR101259499B1 (en) | 2012-06-01 | 2013-05-06 | (주)다인내추럴 | Compositions for improving blood circulation comprising fat-soluble ingredients of ginseng |
| KR20150103690A (en) * | 2013-01-18 | 2015-09-11 | (주)퓨젠바이오농업회사법인 | Method for preparing extract from culture medium of ceriporia lacerata and pharmaceutical composition prepared thereby for preventing or treating diabetic diseases and diabetic complications, which contains extract from culture medium of ceriporia lacerata as active ingredient |
| KR101444614B1 (en) * | 2013-08-01 | 2014-09-26 | 계명대학교 산학협력단 | Method for producing fermented material with high GABA by mixed culture of Ceriporia lacerata and Lactobacillus |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11819510B2 (en) | 2020-09-14 | 2023-11-21 | Advanced Protein Technologies Corp. | Food composition for ameliorating cerebrovascular diseases containing 2′- fucosyllactose and pharmaceutical composition for preventing or treating cerebrovascular diseases containing 2′-fucosyllactose |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017061819A1 (en) | 2017-04-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11197903B2 (en) | Composition containing a bean extract for improving blood circulation and vascular health and method for improving blood circulation and vascular health | |
| KR101682108B1 (en) | Composition for blood flow improvement comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR101655878B1 (en) | Composition for preventing hair loss and enhancing hair growth comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| US10226494B2 (en) | Antioxidant composition containing extracellular polysaccharide produced using Ceriporia lacerata as active ingredient | |
| KR101712590B1 (en) | Composition for relieving fatigue comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| WO2016010182A1 (en) | Composition for improving liver function comprising as active ingredient exopolysaccharide derived from extract from culture medium of ceriporia lacerata | |
| KR20160008431A (en) | Composition for improvement of lipid-related metabolic function comprising exopolysaccharide derived from ceriporia lacerata culture broth extracts as an active ingredient | |
| KR101523139B1 (en) | Composition containing rice bran fermented extract for prevention or treatment of cardiovascular disease | |
| KR101682093B1 (en) | Blood pressure reducing composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR101691972B1 (en) | Pharmaceutical composition for the prevention or treatment of a cancer comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR101682096B1 (en) | Tranquilizer composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR101737626B1 (en) | Composition for immunosuppression comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR101682104B1 (en) | Composition for kidney protection comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR101691975B1 (en) | Pharmaceutical composition for the prevention or treatment of neurodegenerative brain diseases comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR101655882B1 (en) | Composition for eliminating hangover comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR101645652B1 (en) | Sexual function improvement composition comprising exopolysaccharide produced by ceriporia lacerata as an active ingredient | |
| KR20230114895A (en) | Composition for prevention or treatment of thrombotic diseases, comprising an extract of Tremella fuciformis as an active ingredient | |
| KR20110108751A (en) | Blood coagulation inhibiting composition comprising extracts of eisenia bicyclis | |
| KR20170122065A (en) | Pharmaceutical composition comprising the extraction of kaempferia parviflora as an effective component for prevention or treatment of thrombosis and health functional food comprising the same | |
| KR20110018568A (en) | A composition comprising cheonggukjang kinase for the prevention and treatment of cerebral infarct | |
| KR20120102349A (en) | Thrombotic dissolving enzyme extracted from phellinus baumii | |
| KR20100018669A (en) | Method for extracting antithrombatic materials from ear mushroom and the antithrombotic extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GRNT | Written decision to grant | ||
| FPAY | Annual fee payment |
Payment date: 20191030 Year of fee payment: 4 |